Compass Therapeutics (CMPX) Stock: Buy, Sell, or Hold?
CMPX - Compass Therapeutics, Inc. Common Stock
$0.86
-0.04 (-4.93%)
▼
5d:
-24.19%
30d:
-64.74%
90d:
-62.59%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
30d
Get Alerted When CMPX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CMPX is down 24.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CMPX is down 24.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CMPX is currently trading at $0.86, which is considered oversold relative to its 30-day fair value range of $1.29 to $2.40.
Technical Outlook: Technically, CMPX is in a strong uptrend. Immediate support is located at $0.83, while resistance sits at $1.88. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.45 (+536.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CMPX is in a strong uptrend. Immediate support is located at $0.83, while resistance sits at $1.88. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.45 (+536.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.29 -
$2.40
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.9%)
- BULLISH: Trading 536.7% below Wall St target ($5.45)
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.29 -
$2.40
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.83
Resistance Level
$1.88
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.59
Wall Street Target
$5.45
(+536.7%)
Share & Embed Analysis
Last updated: October 04, 2026 12:58 PM ET
Data refreshes hourly during market hours. Next update: 1:58 PM
Data refreshes hourly during market hours. Next update: 1:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CMPX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
23 analysts |
$257 | 53 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 73 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$74 | 60 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
20 analysts |
$95 | 57 HOLD |
|
SNDX
Syndax Pharmaceuticals I… |
STRONG BUY
12 analysts |
$38 | 70 BUY |
